← Back to Search

Protein Kinase Inhibitor

Adavosertib and Gemcitabine for Pancreatic Cancer

Phase 2
Waitlist Available
Research Sponsored by James Cleary, MD, PhD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must have progressed on a platinum-based regimen prior to enrolling on the trial.
Participants must have a histologically confirmed advanced pancreatic adenocarcinoma that is not curable with standard approaches based on the judgement of the treating investigator. Patients with metastatic pancreatic cancer and unresectable pancreatic cancer are eligible.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 8 weeks during treatment, followed for survival after treatment discontinuation up to 2 years
Awards & highlights

Study Summary

This study is being done to test the safety and effectiveness of combining Adavosertib and Gemcitabine in patients with pancreatic cancer. The names of the study drugs involved in this study are: Adavosertib Gemcitabine

Eligible Conditions
  • Pancreatic Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 8 weeks during treatment, followed for survival after treatment discontinuation up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and every 8 weeks during treatment, followed for survival after treatment discontinuation up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Response Rate (ORR)
Secondary outcome measures
Disease Control Rate (DCR)
Incidence of Grade 3 or Higher Treatment-Related Toxicity
Overall Survival (OS)
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Adavosertib and GemcitabineExperimental Treatment2 Interventions
Participants will receive: Adavosertib 1x per day on days 2, 3, 9, 10, 16, and 17 of every 28 day study cycle. Gemcitabineon on days 1,8, and 15 of every 28-day cycle
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Adavosertib
2015
Completed Phase 2
~570
Gemcitabine
2017
Completed Phase 3
~2070

Find a Location

Who is running the clinical trial?

James Cleary, MD, PhDLead Sponsor
1 Previous Clinical Trials
46 Total Patients Enrolled
AstraZenecaIndustry Sponsor
4,238 Previous Clinical Trials
288,471,421 Total Patients Enrolled
Lustgarten FoundationOTHER
23 Previous Clinical Trials
5,376 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~0 spots leftby Mar 2025